We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.79% | 62.50 | 62.00 | 63.00 | 62.50 | 62.50 | 62.50 | 2,827 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.36 | 44.11M |
TIDMTRX
RNS Number : 1940A
Tissue Regenix Group PLC
22 December 2017
Tissue Regenix Group Plc
Issue of equity and total voting rights
Leeds, 22 December 2017 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company, announces that it has today issued and allotted 8,307,608 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted in respect of a 2010 EMI award.
The 8,307,608 new ordinary shares will rank pari passu with the existing ordinary shares and application has been made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00a.m. on Friday 29 December 2017.
Total Voting Rights
Following the issue of the 8,307,608 new ordinary shares, the Company will have a total of ordinary 1,170,990,924 ordinary shares of 0.5p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330 Steve Couldwell CEO 430 3073 Caitlin Pearson Head of Communications / 07920272441 ======================================== ================ Jefferies International Ltd Tel: 020 Simon Hardy / Chris Binks 7029 8000 FTI Consulting Tel: 0203 Brett Pollard/ Mo Noonan / Rob Winder 727 1000 ======================================== ================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEKLLBLDLFBFBE
(END) Dow Jones Newswires
December 22, 2017 04:30 ET (09:30 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions